Prognostic and Immunological Role of LASP2 in Clear Cell Renal Cell Carcinoma

Overview

Journal Genes Genomics

Specialty Genetics

Date 2024 Dec 23

PMID 39714590

Authors

Libo Chen

Nanhui Chen

Zhouzhou Xie

Yuchen Xiao

Huiming Jiang

Affiliations

Soon will be listed here.

Abstract

Background: Clear cell renal cell carcinoma (ccRCC) represents a common renal carcinoma subtype influenced by the immune microenvironment. LIM and SH3 Protein 2 (LASP2), an actin-binding protein within the nebulin family, contributes to cellular immunity and adhesion mechanisms.

Objective: This study aimed to clarify the immunological and prognostic relevance of LASP2 in ccRCC.

Methods: Using clinical and expression data from TCGA, LASP2 expression levels were analyzed alongside clinicopathological features in ccRCC patients. Validation was conducted through real-world samples and tissue microarrays. Comprehensive analysis using online databases examined genetic mutations, DNA methylation patterns, and immune microenvironment characteristics. Gene set enrichment analysis (GSEA) provided insights into LASP2's potential mechanisms in ccRCC.

Results: LASP2 expression was notably reduced and correlated with adverse clinicopathological features and prognosis in ccRCC patients. Prognostic associations were identified across multiple CpG DNA methylation sites. LASP2 levels showed significant correlations with immune cell infiltration and checkpoint genes, including PDCD1 and CTLA4. GSEA findings highlighted LASP2's enrichment within metabolic pathways and signaling networks, such as fatty acid metabolism, TGF-β signaling, and epithelial-mesenchymal transition.

Conclusion: LASP2 emerged as an immune-associated biomarker linked to poorer survival outcomes in ccRCC, suggesting its potential as a novel anti-cancer target and prognostic indicator in ccRCC.

References

Linehan W, Ricketts C . The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications. Nat Rev Urol. 2019; 16(9):539-552. DOI: 10.1038/s41585-019-0211-5. View

Grunewald T, Butt E . The LIM and SH3 domain protein family: structural proteins or signal transducers or both?. Mol Cancer. 2008; 7:31. PMC: 2359764. DOI: 10.1186/1476-4598-7-31. View

Katoh M, Katoh M . Identification and characterization of LASP2 gene in silico. Int J Mol Med. 2003; 12(3):405-10. View

Butt E, Raman D . New Frontiers for the Cytoskeletal Protein LASP1. Front Oncol. 2018; 8:391. PMC: 6160563. DOI: 10.3389/fonc.2018.00391. View

Sala S, Ampe C . An emerging link between LIM domain proteins and nuclear receptors. Cell Mol Life Sci. 2018; 75(11):1959-1971. PMC: 11105726. DOI: 10.1007/s00018-018-2774-3. View

Stradal T, Scita G . Protein complexes regulating Arp2/3-mediated actin assembly. Curr Opin Cell Biol. 2005; 18(1):4-10. DOI: 10.1016/j.ceb.2005.12.003. View

Chen L, Wang J, Fan X, Zhang Y, Zhoua M, Li X . LASP2 inhibits trophoblast cell migration and invasion in preeclampsia through inactivation of the Wnt/β-catenin signaling pathway. J Recept Signal Transduct Res. 2020; 41(1):67-73. DOI: 10.1080/10799893.2020.1787444. View

Yang Y, Nie L, Wei Q, Li W . LASP2 functions as a potential prognostic factor and therapeutic target in nasopharyngeal carcinoma. Eur Rev Med Pharmacol Sci. 2020; 24(18):9416-9422. DOI: 10.26355/eurrev_202009_23026. View

Li J, Hu S, Zhang Z, Qian L, Xue Q, Qu X . LASP2 is downregulated in human liver cancer and contributes to hepatoblastoma cell malignant phenotypes through MAPK/ERK pathway. Biomed Pharmacother. 2020; 127:110154. DOI: 10.1016/j.biopha.2020.110154. View

10.

Zhang X, Cai L, Zhou H, Liu Y, Fan C, Wang L . Lasp2 enhances tumor invasion via facilitating phosphorylation of FAK and predicts poor overall survival of non-small cell lung cancer patients. Mol Carcinog. 2017; 56(12):2558-2565. DOI: 10.1002/mc.22700. View

11.

Jiang H, Chen H, Wan P, Chen N . Decreased expression of HADH is related to poor prognosis and immune infiltration in kidney renal clear cell carcinoma. Genomics. 2021; 113(6):3556-3564. DOI: 10.1016/j.ygeno.2021.08.008. View

12.

Zhang Y, Zhang L . Knockdown of LASP2 inhibits the proliferation, migration, and invasion of cervical cancer cells. J Cell Biochem. 2019; 120(9):15389-15396. DOI: 10.1002/jcb.28806. View

13.

Zhang Y, Li J, Yuan Q, Cao G, Yang W . Upregulation of LASP2 inhibits pancreatic cancer cell migration and invasion through suppressing TGF-β-induced EMT. J Cell Biochem. 2019; 120(8):13651-13657. DOI: 10.1002/jcb.28638. View

14.

Wang B, Zhang L, Zhao L, Zhou R, Ding Y, Li G . LASP2 suppresses colorectal cancer progression through JNK/p38 MAPK pathway meditated epithelial-mesenchymal transition. Cell Commun Signal. 2017; 15(1):21. PMC: 5469134. DOI: 10.1186/s12964-017-0179-9. View

15.

Aggarwal V, Montoya C, Donnenberg V, Sant S . Interplay between tumor microenvironment and partial EMT as the driver of tumor progression. iScience. 2021; 24(2):102113. PMC: 7892926. DOI: 10.1016/j.isci.2021.102113. View

16.

Choi C, Finlay D . Optimising NK cell metabolism to increase the efficacy of cancer immunotherapy. Stem Cell Res Ther. 2021; 12(1):320. PMC: 8180160. DOI: 10.1186/s13287-021-02377-8. View

17.

Raskov H, Orhan A, Christensen J, Gogenur I . Cytotoxic CD8 T cells in cancer and cancer immunotherapy. Br J Cancer. 2020; 124(2):359-367. PMC: 7853123. DOI: 10.1038/s41416-020-01048-4. View

18.

Mittal V . Epithelial Mesenchymal Transition in Tumor Metastasis. Annu Rev Pathol. 2018; 13:395-412. DOI: 10.1146/annurev-pathol-020117-043854. View

19.

Deng X, Norris A, Panaviene Z, Moncman C . Ectopic expression of LIM-nebulette (LASP2) reveals roles in cell migration and spreading. Cell Motil Cytoskeleton. 2008; 65(10):827-40. PMC: 2603443. DOI: 10.1002/cm.20304. View

20.

Dongre A, Weinberg R . New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2018; 20(2):69-84. DOI: 10.1038/s41580-018-0080-4. View